ReleaseWire

Global Perphenazine Sales Market Will Reach 100 Million US$ by the End of 2025

Global Perphenazine Sales Market report contains a complete product overview and its scope in the market to define the key terms and provide the clients a holistic idea of the market and its tendency.

Posted: Tuesday, June 26, 2018 at 3:53 AM CDT

City of Industry, CA -- (SBWire) -- 06/26/2018 --This report studies the global Perphenazine market status and forecast, categorizes the global Perphenazine market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America).

Perphenazine is a typical antipsychotic drug. Chemically, it is classified as a piperazinyl phenothiazine. Originally marketed in the US as Trilafon, it has been in clinical use for decades. Perphenazine is roughly five times as potent as chlorpromazine, thus perphenazine is considered a medium-potency antipsychotic.

The global average price of Perphenazine is in the decreasing trend, from 6.95 USD/Unit in 2012 to 7.08 USD/Unit in 2016. With the situation of global economy, prices will be in increasing trend in the following five years.

Request Sample Copy of the Report @ https://www.qyresearch.com/sample-form/form/523606/global-perphenazine-sales-market

The classification of Perphenazine includes Oral Forms and Injectable Solution, and the proportion of Oral Forms in 2016 is about 98%.

Perphenazine is widely used to treat psychosis and antiemetic. The most proportion of Perphenazine is used to treat psychosis, and the proportion in 2016 is 95%.

North America is the largest consumption place, with a consumption market share nearly 39% in 2015. Following North America, Asia Pacific is the second largest consumption place with the consumption market share of 25%.

Market competition is not intense. Teva, Sandoz, Endo, Mylan, ZHPHARMA, Shandong Boshan Pharma, etc. are the leaders of the industry, with high-end customers; have been formed in the monopoly position in the industry.

The global Perphenazine market is valued at 95 million US$ in 2017 and will reach 100 million US$ by the end of 2025, growing at a CAGR of 0.6% during 2018-2025.

Ask for Discount on Research Report@ https://www.qyresearch.com/request-discount/form/523606/global-perphenazine-sales-market

The major players covered in this report

Teva

Sandoz

Endo

Mylan

ZHPHARMA

Shandong Boshan Pharma

...

Geographically, this report studies the key regions, focuses on product sales, value, market share and growth opportunity in these regions, covering

United States

Europe

China

Japan

Southeast Asia

India

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

Oral Forms

Injectable Solution

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

Psychosis

Antiemetic

Click to view the full report TOC, figure and tables: https://www.qyresearch.com/index/detail/523606/global-perphenazine-sales-market